In addition, 25% of ATM BCs and 21.4% of CHEK2 BCs were observed to be HER2 positive, while only 18.8% of the ATM BCs and none of the the CHEK2 tumors were accounted for as triple negative BC. The gene discussed is ERBB2; the disease is breast cancer.